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Abstract
Purpose: The goal of the current investigation was to compare complex 3Dconformal plans generated on Eclipse™ treatment planning system (TPS) withindependent dose calculations from radiation oncology planning system (ROPS™)TPS used as a secondary quality assurance check. Methods: Fifteen cancer patientsthat were treated with complex conformal treatment plans with cobalt and linacbeams, using Eclipse TPS, were selected for this study. The structure sets,treatment beam data and prescription information were exported from the EclipseTPS using DICOM-RT export. Using custom software, these data were imported intoROPS TPS. Independent dose calculation on the ROPS planning system usingClarkson summation algorithm was done. The dose volume histograms (DVH) fromboth planning systems were extracted and analyzed using custom software. Doseassessment was accomplished by defining criteria based on gross tumor volume(GTV) dose coverage, dose homogeneity and mean dose. For organs at risk (OAR)other than GTV, the main dose parameters were, mean dose and percentage ofvolume receiving 95% of prescription dose. Results: For the GTV, all 15 cases metthe criteria set for the mean dose and dose homogeneity index. However, breastcases were found to have deviation in the percentage volume receiving the 95% ofprescription dose. Conclusion: Using the criteria set for plan acceptance, all the 15clinical cases were evaluated. Except for breast tangent plans, all plans passed allthe criteria set. The large deviation for breast tangent plans was attributed todifferences in dose calculation algorithms.
Keywords: Quality Assurance, 3D Treatment Planning, DVH analysis, Eclipse TPS,ROPS TPS
1. IntroductionModern 3D planning is more complex than in the past.The complexity arises due to the fact, the use of MLCwith fine leaves allows the exploitation of irregularshaped beams, wedged beams with physical as well asenhanced dynamic wedges, including field-in-field beamconfigurations. Sometimes non-coplanar arrangementwith table and collimator angles is used. Once, the 3Dplan is generated, unlike IMRT, there are no specificregulations for the verification of these plans before thepatient is treated. Independent dose calculations usinghand calculations1 has many limitations due to thecomplexity of these fields. Even experimentalmeasurements using hybrid plan and planar dosedistribution measurements verify the phantom dose
only and do not directly related to actual dose receivedby the patient. Under these circumstances, it is highlydesirable to verify the entire plan in anotherindependent planning system. Dose-volume histogramsprovide key information to radiation oncologists whenthey assess the adequacy of a patient treatment plan inradiation therapy.The use of dose volume histograms alone has its pitfallsespecially they lack the positional information. This hasbeen described by Kessler et al.2 In addition, dosevolume histograms do carry errors propagated throughseveral parameters, such as dose grid and these havebeen examined by Panitsa et al.3 While the DVH data
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suffers from loss of position detail, it has its merits inallowing various biological models based on tumorcontrol probability (TCP) and normal tissuecomplication probability (NTCP) concepts described byseveral investigators.4, 5, 6, 7 In order to use the DVH datain a concise manner several dose indices were defined.Feuvret et al.8 defined conformity index. Leung et al.9defined conformation number (CN) and conformal index(COIN). The radiation conformity index was defined byKnoos et al.10Pyakuryal et al.11 developed HART tool forDVH analysis. Weinberg et al.12 investigated the sourceof differences in DVH generation in planning systems.The uncertainties in DVH were also investigated byHenriquez et al.13 There are not many investigations thatreported the DVH comparison of different treatmentplanning systems for the same patient data includingsame beam plan configuration. Nelms et al.14 reportedcomparison of DVH between Pinnacle and PlanIQ usingvery similar geometrical targets. Ayyangar et al.15reported DVH comparison of the same patients in twodifferent planning systems viz. Pinnacle and Corvus.They reported deviations as much as 15% for organs atrisk other than CTV/GTV.Comparing the DVHs of GTV as well as all otherstructures independently is a much better approachthan point dose calculation or hybrid plan evaluation.Nelson et al.16 have described an independent TPSverification system based on DICOM-RT transfer andconvolution algorithm. The system generatesindependent DVH for comparison with Eclipse system.Many Commercial systems, MOBIUS™ (Mobius MedicalSystems, Houston, TX), COMPASS™ (IBA, Inc) 3DVH (SunNuclear Corporation), RayStation (RaySearchLaboratories, Stockholm, Sweden) RadCalc(®) (LifeLineSoftware Inc., Austin, USA) currently have similarsoftware that use patient data transfer from the TPS.Unfortunately there are not many publications thatcompared DVH analysis of several patientsinter-comparing these systems.In a recent paper by Anil Kumar et al.17, a qualityassurance method for treatment plan verification wasdescribed.  This method exported structure sets andplan data from Eclipse planning system into the ROPSplanning system. On the ROPS system, the dose wasre-calculated and the DVH were generated. The DVHsfrom both planning systems were compared using Excelspreadsheet. Since it was comparison of two
independent planning systems, the monitor units were
not identical. In this current paper more detailedevaluation of this method was attempted using 10clinical cases that used linac machine and 5 clinical casesthat used cobalt-60 machine. Since the method in thequoted paper was for doing quality assurance, in thecurrent paper, all DVHs were computed on the ROPS TPSusing the same monitor units as with the Eclipse plans..
2. Methods and Materials
In the current investigation, all the Eclipse plans usedversion 8.8 using AAA algorithm, except for four plansthat used the new version 13.6. All plans used tissueheterogeneity correction. For each patient plan, the CTscans were directly imported into ROPS from the Eclipsesystem using the scan export. Next, for each patient, thestructure sets and plan information from the Eclipsesystem were exported using DICOM-RT as ASCII files.Using custom software written for the ROPS planningsystem, these data were re-formatted so it can be readby the ROPS planning system.
2.1. ROPSROPS TPS is based on CENTOS 6.4 Linux operatingsystem and was commissioned using BJR25 depth dosefor Cobalt-60 machine. The dose rate, output factors,wedge factors etc. were specific to the actual treatmentmachine that was used. For LINAC, data from a specificVarian DHX (Dual Head X-Ray) machine was used forcommissioning18 the TPS. Comprehensive treatmentplanning tests were performed using TG-53 report. Fordose calculations, ROPS uses Clarkson scatterintegration method. ROPS corrects for tissueheterogeneity by using ray traced equivalent depth.The details of ROPS specifications can be found from thewebsite at https://sites.google.com/site/tjcsrops. Theuse of ROPS for conformal treatments has been recentlyreported.19The DICOM-RT regions of interest file consisted of allregions contoured as well as body contours. The dosefile consisted of dose volume histograms and the dose tomatrix matching each CT image. The plan file consistedof beam parameters such as field sizes, beam angles,wedges, MLC positions, beam weights, dose prescription,number of fractions and monitor units and isocenterposition. Using all this information, the ROPS systemcalculated the dose to the matrix and the dose volumehistograms. After the DVH calculations, the analysisconsisted of calculating some important dosimetricparameters. This analysis was performed using the datafrom both planning systems, but outside the planningsystems using Excel spread sheets and custom software.The following describes the parameters and the criteriadefined for the comparison of the DVHs. The V95 is thepercent volume receiving 95% prescription dose. If thedifference between the two systems is less than 5, thetarget dose coverage was considered in agreement.The dose homogeneity index HI in the target volume wascalculated using(D5 - D95)/Dp *100 where D5 and D95 represent thedose at 5% and 95% target volume respectively and Dpis the prescription dose. Similar definition was used byYoon et al.20 and Kataria et al.21 If the difference in HIbetween the planning systems is less than 5%, the targetdose distribution uniformity was considered inagreement. In addition, the mean dose to the target was
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also compared. If the ratio between the mean doses ofthe two systems is between 0.95 and 1.05, the targetdose was considered in agreement.For each structure other than the target volume, themaximum dose, the minimum dose, the volumeaveraged mean dose and V95 were computed. If thedifference in V95 between the two systems is less than 5,the structure dose coverage was considered inagreement. The difference between the mean dosesbetween the two planning systems was computed andwas considered in agreement if it is less than 5 Gy.
3. ResultsTable 1 shows the results of the DVH analysis for thetarget volume for all the 15 clinical cases. The regionsspecified in column 4 already contained adequatemargins and are to be considered as equivalent to PTVfor all practical purposes. The doses are displayed inunits of Gy. The differences in V95 are red color coded ifthe difference is 5 or more indicating there is 5% orgreater difference in the target coverage between boththe planning systems. Similarly, HI and mean dose werered color coded, if the criteria were not met. The averageand standard deviation of the comparison between thetwo planning systems is also listed in Table 1. Inaddition, the p - value from two tailed paired t - test wasalso computed between the Eclipse and ROPS indices. Ascan be seen from the Table (column 7), as well as fromFigure 1, the dose homogeneity index is within the setcriteria.The difference in V95 between the planning systemsfrom Table 1 column 6 is plotted in Figure 2. We findthat only one case out 15 cases did not meet the criteria.This case involves breast plan where the GTV is notcovered fully at the 90-95% dose level. This is because ofthe sloping contour in both medial-lateral as well ascraniocaudal direction. The use of traditional wedgesdoes not bring dose uniformity. Figure 3 shows the DVHcomparison for this case of breast treatment. It can beseen that the GTV is covered by the prescription doseonly at 60-70% level instead of expected 95% isodoseline. ROPS calculation shows an increase in dose of 3 Gyat the 40% volume. It is interesting even though thedifference in V95 is excessive, the homogeneity indexand mean dose are within limits between the twoplanning systems.
Figure 1: The difference between Eclipse and ROPS in doseuniformity index for the GTV
Figure 2: Difference between Eclipse and ROPS in V95(percent volume receiving 95% dose)
Figure 3: DVH comparison of breast GTV for case#9.Eclipse thick line and ROPS in thin line.
Figure 4: Mean dose ratio between Eclipse and ROPS forthe GTV of the clinical plans.
Figure 5: DVH comparison of breast GTV for case#10.Eclipse thick line and ROPS in thin line.
Table 1: DVH parameter analysis for GTV. Parameter values that did not meet the set criteria were marked in redcolor.PatientNumber Energy TreatmentSite Region ofInterest TPS V95(%) HI MeanDose(Gy) D5(Gy) D95(Gy) PrescriptionDose (Gy)1 6MV16MV Ca bladder CTV Eclipse 100.0 3.1 50.5 51.8 50.2 50CTV ROPS 100.0 4.4 50.9 53.0 50.8 50diff/ratio 0.0 -1.3 1.02 6MV Ca bladder Bladder1.5margin Eclipse 98.3 5.3 43.5 51.1 48.5 50Bladder1.5margin ROPS 99.0 4.5 44.0 53.1 50.8 50diff/ratio -0.7 0.7 1.03 16MV Ca lung GTV Eclipse 98.1 7.7 40.5 46.3 42.9 44GTV ROPS 100.0 5.9 41.0 45.5 43.0 44diff/ratio -1.9 1.8 1.04 6MV Lung LUNG &METS Eclipse 100.0 7.0 47.2 52.3 48.8 50ROPS 99.0 8.3 46.8 52.6 48.5 50diff/ratio 1.0 -1.3 1.05 6MV Lung LT LUNG Eclipse 95.7 9.9 47.6 52.6 47.7 50ROPS 99.0 13.3 48.8 56.0 49.3 50diff/ratio -3.3 -3.4 1.06 6MV Lung RT LUNG Eclipse 99.7 8.1 61.6 68.3 64.3 50ROPS 100.0 10.5 64.3 69.1 63.8 50diff/ratio -0.3 -2.5 1.07 16MV Caesophagus GTV Eclipse 100.0 4.4 39.9 41.3 39.5 40GTV ROPS 100.0 5.0 38.7 40.5 38.5 40diff/ratio 0.0 -0.6 1.08 6MV16MV Caesophagus GTV Eclipse 100.0 5.5 38.8 40.6 38.4 40GTV ROPS 97.0 9.3 31.6 44.7 41.0 40diff/ratio 3.0 -3.8 1.29 6MV Ca lt.breast GTV Eclipse 56.2 104.9 24.3 53.0 0.5 50GTV ROPS 64.0 108.0 25.0 55.4 1.3 50diff/ratio -7.8 -3.1 1.010 6MV Breast LTBREAST Eclipse 93.5 14.4 34.0 54.2 47.0 50ROPS 91.0 10.6 26.1 47.8 42.4 50diff/ratio -0.3 3.8 1.311 Cobalt-60 Cervicalspine GTV Eclipse 97.5 11.0 58.3 63.2 56.7 59.4ROPS 98.0 9.3 57.8 62.6 57.1 59.4diff/ratio -0.5 1.7 1.012 Cobalt-60 Abdomen GTV Eclipse 100.0 5.1 48.1 52.2 49.7 50GTV ROPS 100.0 5.4 46.9 52.0 49.3 50diff/ratio 0.0 -0.3 1.013 Cobalt-60 Abdomen GTV Eclipse 38.0 98.8 18.8 40.0 0.5 40GTV ROPS 42.0 99.5 18.4 40.4 0.6 40diff/ratio -4.0 -0.7 1.014 Cobalt-60 Rt post.brain GTV2 Eclipse 99.8 4.3 29.2 30.6 29.3 30ROPS 100.0 5.8 29.3 31.1 29.4 30diff/ratio -0.3 -1.5 1.015 Cobalt-60 Cervicalspine GTV Eclipse 95.8 13.5 10.2 21.7 19.1 19.8GTV ROPS 99.0 9.2 10.1 21.5 19.6 19.8diff/ratio -3.2 4.3 1.0Average -1.2 -0.4 1.0Std. dev 2.5 2.5 0.1p-value 0.164 0.536 0.281
Table 2: DVH parameter analysis for critical structures. Parameter values that did not meet the set criteria were markedin red color.
PatientNumber Structure TPS V95 (%) MaximumDose(Gy) MinimumDose(Gy) Mean Dose(Gy)1 Rectum Eclipse 75.0 52.42 34.05 42.07Rectum ROPS 71.0 54.14 32.18 41.28diff 4.0 -1.72 1.87 0.792 Bladder Eclipse 100.0 51.24 48.27 49.22Bladder ROPS 100.0 52.91 50.24 50.98diff 0.0 -1.67 -1.97 -1.763 Spinal Cord Eclipse 45.8 45.59 0.54 21.01Spinal Cord ROPS 47.0 45.09 0.45 20.73diff -1.2 0.50 0.09 0.284 Heart Eclipse 0 3.3 0.21 0.65Heart ROPS 0 3.5 0.5 0.95diff 0.0 -0.20 -0.29 -0.30Lt. lung Eclipse 9.62 52.81 0.22 18.77Lt. lung ROPS 11 53.5 0 17.62diff -1.4 -0.69 0.22 1.15PTV Eclipse 99.46 53.37 42 46.18PTV ROPS 100 53.5 32.5 41.39diff -0.5 -0.13 9.50 4.79Rt. lung Eclipse 0 23.29 0.14 3.23Rt. lung ROPS 0 23 0 2.51diff 0.0 0.29 0.14 0.72Spinal cord Eclipse -0.02 31.34 0 8.54Spinal cord ROPS 0 27.5 0 7.77diff 0.0 3.84 0.00 0.77Lung-GTV Eclipse 8.89 52.7 0.22 18.57Lung-GTV ROPS 11 53.5 0 17.48diff -2.1 -0.80 0.22 1.09Shell Eclipse 0.46 50.34 1.51 15.03Shell ROPS 22 53.5 1 18.89diff -21.5 -3.16 0.51 -3.864mm Eclipse 90.08 53.38 31.15 40.424mm ROPS 92 53.5 25 37.17diff -1.9 -0.12 6.15 3.252mm Eclipse 96.53 53.37 34.94 42.52mm ROPS 98 53.5 28 38.95diff -1.5 -0.13 6.94 3.55PTV50Gy Eclipse 99.46 53.38 42.01 46.18PTV50Gy ROPS 100 53.5 32.5 41.39diff -0.5 -0.12 9.51 4.796mm Eclipse 80.91 53.37 23.9 36.56mm ROPS 84 53.5 16.5 32.5diff -3.1 -0.13 7.40 4.005 Spinal cord Eclipse -0.11 26.06 0 9.58Spinal cord ROPS 0 25 0 8.14diff -0.1 1.06 0.00 1.44Rt. lung Eclipse 0 20.65 0 3.5Rt. lung ROPS 0 20 0 3.33diff 0.0 0.65 0.00 0.17Lt. lung Eclipse 4.49 52.72 0.61 15.28Lt. lung ROPS 9 57.5 0.5 16.23diff -4.5 -4.78 0.11 -0.95Heart Eclipse 1.25 51.76 1.56 11.71Heart ROPS 1 52.5 1 10.91diff 0.3 -0.74 0.56 0.80Esophagus Eclipse -0.45 32.62 0.39 10.65
Esophagus ROPS 0 32.5 0.5 9.73diff -0.5 0.12 -0.11 0.92PTV50Gy Eclipse 95.73 53.25 44.4 47.58PTV50Gy ROPS 99 57.5 44.5 48.76diff -3.3 -4.25 -0.10 -1.18Lung-GTV Eclipse 4.25 52.56 0.61 15.2Lung-GTV ROPS 9 57.5 0.5 16.61diff -4.8 -4.94 0.11 -1.416 Esophagus Eclipse -0.15 30.85 0.41 8.1Esophagus ROPS 0 29.04 0 6.63diff -0.2 1.81 0.41 1.47GTV Eclipse 100 69.21 64 65.57GTV ROPS 100 72.6 62.04 64.33diff 0.0 -3.39 1.96 1.24Heart Eclipse -0.01 37.79 0.11 8.41Heart ROPS 0 35.64 0 6.72diff 0.0 2.15 0.11 1.69Lung Rt-GTV Eclipse 13.91 69.33 0.51 24.78Lung-Rt-GTV ROPS 20 73.26 0 24.65diff -6.1 -3.93 0.51 0.13Lung_Lt. Eclipse -0.02 24.83 0.24 4.05Lung_Lt. ROPS 0 31.68 0 3.22diff 0.0 -6.85 0.24 0.83Lung_Rt. Eclipse 15.63 69.34 0.51 25.22Lung_Rt. ROPS 20 73.26 0 24.68diff -4.4 -3.92 0.51 0.54PTV 66PHY Eclipse 96.08 70.52 57.84 62.05PTV-66 ROPS 99 73.26 50.82 58.58diff -2.9 -2.74 7.02 3.47Spinal Canal Eclipse -0.1 43.71 0.13 17.66Spinal Canal ROPS 0 42.24 0 14.91diff -0.1 1.47 0.13 2.757 Spinal cord Eclipse 0.0 33.82 0.00 11.45Spinal cord ROPS 0.0 34.82 0.39 11.63diff 0.0 -1.00 -0.39 -0.18Heart Eclipse 71.6 42.54 21.37 30.62Heart ROPS 70.0 41.79 17.41 27.62diff 1.6 0.75 3.96 3.00Liver Eclipse 27.0 42.67 0.66 15.45Liver ROPS 35.0 42.56 0.39 16.02diff -8.0 0.11 0.27 -0.57Lt. Kidney Eclipse 0.0 37.39 1.34 12.24Lt. Kidney ROPS 0.0 38.69 0.77 12.00diff 0.0 -1.30 0.57 0.24Rt. Kidney Eclipse 0.0 19.42 0.60 3.19Rt. Kidney ROPS 0.0 23.60 0.39 2.86diff 0.0 -4.18 0.21 0.338 Cord Eclipse 50.97 42.14 0.07 19.28Cord ROPS 40 44.1 0 18.61diff 11.0 -1.96 0.07 0.679 Lt. lung Eclipse 0 47.8 0.48 17.33Lt. lung ROPS 4 51.5 0.76 18.23diff -4.0 -3.70 -0.28 -0.90Rt. lung Eclipse -0.01 4.57 0 0.32Rt. lung ROPS 0 11.44 0.38 1diff 0.0 -6.87 -0.38 -0.68Heart Eclipse 0.01 47.6 0.48 17.53Heart ROPS 4 51.5 1.14 17.59diff -4.0 -3.90 -0.66 -0.06Spinal cord Eclipse -1.85 0.42 0.02 0.14Spinal cord ROPS 0 4.96 0.57 0.87diff -1.9 -4.54 -0.55 -0.7310 Lung_Lt. Eclipse 10.72 52.84 1.48 20.33Lung_Lt. ROPS 14 55.67 0.85 20.82diff -3.3 -2.83 0.63 -0.49Heart Eclipse 5.1 53.41 1.81 17.8Heart ROPS 5 55.89 1.06 16.19diff 0.1 -2.48 0.75 1.61Spinal Cord Eclipse -0.03 1.71 0.62 0.94
Spinal Cord ROPS 0 1.49 0.64 0.9diff 0.0 0.22 -0.02 0.04Lung_Rt. Eclipse 0 24.07 0 0.96Lung_Rt. ROPS 0 41.65 0.64 1.3diff 0.0 -17.58 -0.64 -0.3411 Spinal cord Eclipse 0.0 12.92 0.00 2.47Spinal cord ROPS 0.0 1.80 0.00 0.38diff 0.0 11.12 0.00 2.0912 Rectum Eclipse 71.3 50.42 8.04 27.80Rectum ROPS 79.0 50.50 6.50 27.02diff -7.7 -0.08 1.54 0.78Bladder Eclipse 100.0 55.29 49.81 51.41Bladder ROPS 100.0 55.50 47.50 49.79diff 0.0 -0.21 2.31 1.6213 Rt. kidney Eclipse -2.1 1.10 0.24 0.44Rt. kidney ROPS 0.0 1.60 0.00 0.41diff -2.1 -0.50 0.24 0.03Bladder Eclipse 0.0 7.61 0.90 1.92Bladder ROPS 0.0 5.20 0.80 1.70diff 0.0 2.41 0.10 0.22Lt. kidney Eclipse -1.3 1.36 0.23 0.46Lt. kidney ROPS 0.0 2.00 0.00 0.43diff -1.3 -0.64 0.23 0.0314 Left eye Eclipse 0.0 0.18 0.10 0.12Left eye ROPS 0.0 0.67 0.00 0.09diff 0.0 -0.49 0.10 0.03Right eye Eclipse 0.0 0.35 0.19 0.23Right eye ROPS 0.0 0.67 0.00 0.22diff 0.0 -0.32 0.19 0.0115 Spine Eclipse 0.0 11.64 0.27 4.33Spine ROPS 0.0 10.49 0.00 3.85diff 0.0 1.15 0.27 0.48Average -1.5 0.7Std.Dev. 4.0 1.6p-value 0.01 0.002
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Figure 6: Difference in mean dose between Eclipse andROPS for all the structures other than the prescription GTV.
Figure 7: Difference between Eclipse and ROPS in V95(percent volume receiving 95% of prescription dose) for allthe structures other than prescription GTV.
Figure 8: DVH comparison of SHELL structure for patient#4. Eclipse thick line and ROPS in thin line.Figure 4 shows the ratio of mean dose (from column 8 ofTable 1) between Eclipse and ROPS for the GTV. It can beseen except for cases #8 and #10, all the ratios indicateagreement within 5%. It appears that we see moredisagreement for the cases of breast and esophagus. TheDVH comparison for case #10 is shown in Figure 5. Thedisagreement in mean dose ratio is caused by lowerdose coverage in ROPS between 90-100% volumes.Table 2 shows comparison data for structures otherthan GTV or CTV. The structure, BODY that representsthe skin on each CT slice has been omitted. Once again,red colored data indicates differences between Eclipseand ROPS using the above specified criteria. Theaverage, standard deviation and p - values of thecomparison between the two planning systems are alsolisted in Table 2.
Figure 6 shows the difference in mean dose (fromcolumn 7 of Table 2) in Gy for all the 52 structures fromthe 15 clinical cases. It can be seen that the variation iswithin 5 Gy. This should be acceptable for thesestructures which are shielded from the GTV. Figure 7shows the difference in V95. It can be seen that 5 out of52 structures are off by more than 5%. The DVH plot forthe structure that is off by 21.6 % is shown in Figure 8. Itcan been that even though the mean dose for thisstructure is within limits, ROPS is indicating higher dosealthough to a smaller volume.
4. DiscussionFrom the statistical analysis shown in Table-1, it is clearthat the p-value is greater than 0.05 indicates that thereis no significant difference in the distributions of meandose values between ROPS and Eclipse planning systemsfor the target structures. However, the p-values in Table-2 clearly show p < 0.05 which indicates, there issignificant deviation in the dose calculated for organsoutside the target volume. This could mean that the dosein penumbra region could be causing this difference.There are many reasons why discrepancies can occurbetween the two planning systems. These are listedbelow.It has been well demonstrated in literature that planningsystems do not calculate the DVH accurately. Severalarticles in the literature22, 23, 24 demonstrated this byusing finer grid calculation. Variations in tumor volumedelineation and volume calculations cause discrepanciesin planning systems.25 While Eclipse uses 512 × 512 CTmatrix, ROPS scales them down to 256 × 256 matrix.This causes error in region boundaries and volumecalculations. In general ROPS volumes are 15% largerthan Eclipse. Differences in the tissue heterogeneitycorrection methods can account for large variationsbetween planning systems.Differences in dose calculation algorithms: While Eclipseused AAA algorithm in the current investigation, ROPSused Clarkson based algorithm for dose calculations.This accounts for the major differences we have seen inthe case of breast and esophagus. The Clarkson dosecalculation method used by ROPS assumes full scatterconditions. However, for breast treatments there isconsiderable amount of missing tissue not only intransverse images but also in craniocaudal direction.Although ROPS accounts for equivalent tissue depth,lateral scatter was not corrected for tissueheterogeneity. The convolution algorithm used byEclipse is relatively more accurate in these cases.While it is desirable to make this comparison with a TPSwith more robust dose calculation model, the mainreason to take up this project was the fact that ROPS wasdescribed17 as a low-cost solution. While improving the
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dose calculation grid makes minor improvements,accurate dose calculation model makes the bulk of thedifference. It is highly desirable that in future the dosecalculation model in ROPS be improved, to make thismore acceptable.
5. ConclusionThis work demonstrates the use of ROPS as a QAverification tool for Eclipse plans. Although theagreement in most cases is quite acceptable, in somecases it is unacceptable due to dose calculationalgorithm differences. While it is desirable to use abetter dose calculation model, in the meanwhile, theROPS system can be used as a verification tool, with thisknowledge.
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